Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0H1AY
|
|||
Former ID |
DIB008884
|
|||
Drug Name |
AQW-051
|
|||
Synonyms |
AQW-051; 669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1], [2] | |
Company |
Novartis AG
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C19H22N2O
|
|||
Canonical SMILES |
CC1=CC=C(C=C1)C2=NC=C(C=C2)OC3CN4CCC3CC4
|
|||
InChI |
1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
|
|||
InChIKey |
NPDLTEZXGWRMLQ-IBGZPJMESA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neuronal acetylcholine receptor alpha-7 (CHRNA7) | Target Info | Agonist | [3] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Cholinergic synapse | ||||
Nicotine addiction | ||||
Chemical carcinogenesis | ||||
Panther Pathway | Alzheimer disease-amyloid secretase pathway | |||
Nicotinic acetylcholine receptor signaling pathway | ||||
Reactome | Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | |||
WikiPathways | SIDS Susceptibility Pathways | |||
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7371). | |||
REF 2 | ClinicalTrials.gov (NCT01474421) Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease. U.S. National Institutes of Health. | |||
REF 3 | AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.